

MEDICLINIC INTERNATIONAL LIMITED  
(Incorporated in the Republic of South Africa)  
(Registration number: 1983/010725/06)  
(Share code: MDC)  
(ISIN: ZAE000074142)  
("Mediclinic" or "the Company")

TRADING STATEMENT - UNAUDITED GROUP RESULTS FOR THE SIX MONTHS  
ENDED 30 SEPTEMBER 2013

Mediclinic is in the process of finalising its interim results for the six months ended 30 September 2013, which are due to be released on SENS on 6 November 2013 and published in the press on 7 November 2013 ("interim results announcement"). In terms of the JSE Limited ("JSE") Listings Requirements, companies are required to publish a trading statement as soon as they are satisfied that a reasonable degree of certainty exists that the financial results for the period to be reported upon next will differ by at least 20% from that of the previous corresponding reporting period.

Accordingly, shareholders are advised that the Company's basic earnings per share ("EPS") and basic headline earnings per share ("HEPS") for the six months ended 30 September 2013 are expected to be between 17% and 27% higher than that reported for the previous corresponding reporting period ("the EPS and HEPS range").

Shareholders are also advised that for the six months ended 30 September 2012, as well as for the year ended 31 March 2013, the income statement and earnings per share have been restated due to:

- the adoption of the revised IAS 19 standard relating to employee benefits; and
- an adjustment to the weighted average number of shares in issue subsequent to the 2012 rights offer in terms of IAS 33 (paragraph 26).

This trading statement will also address normalised HEPS, which is defined as reportable HEPS in terms of accounting standards, excluding one-off items.

The one-off items included in calculating the EPS and HEPS range are the following:

- a past service cost credit in one of the Group's pension funds in the current period; and
- net unrealised gains on foreign exchange forward contracts in the previous period.

Excluding these one-off items, the normalised HEPS for the six months ended 30 September 2013 are expected to be between 30% and 40% higher than that reported in the previous corresponding

reporting period and between 53% to 63% higher than the restated numbers of the previous corresponding reporting period.

The financial information on which this trading statement is based has not been reviewed and reported on by the Company's external auditors.

Stellenbosch  
28 October 2013

Mediclinic Offices, Strand Road, Stellenbosch 7600, South Africa  
PO Box 456, Stellenbosch 7599, South Africa  
Tel +27 21 809 6500  
Fax +27 21 886 4037  
Ethics line: 0800 005 316  
Website: [www.mediclinic.com](http://www.mediclinic.com)

Sponsor  
RAND MERCHANT BANK (A division of FirstRand Bank Limited)